Latest Naloxone Stories
RALEIGH, N.C., March 2, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced the positive outcome of a pre-Investigational New Drug (pre-IND) meeting with the U.S.
WARREN, N.J., Feb.
Helping to address the issue of medication adherence, persons with opioid dependence who had the medication buprenorphine implanted had less opioid use over 16 weeks.
BALTIMORE, Sept. 16 /PRNewswire/ -- Findings from a new national survey, sponsored by the American Pain Foundation, reveal misperceptions among physicians regarding the misuse and abuse of opioids. The results come in light of government statistics to be released today looking at the broader U.S.
STAMFORD, Conn., Sept. 9 /PRNewswire/ -- Purdue Pharma L.P. will present data from the clinical program for Butrans(TM) (buprenorphine) Transdermal System CIII in a series of posters at PAINWeekÂ® 2010, September 8-10 in Las Vegas. Butrans recently received marketing approval from the U.S.
WARREN, N.J., Aug.
SOUTH SAN FRANCISCO, Calif., March 30 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (Pink Sheets: TTNP) today announced the initiation of a randomized, placebo and active controlled, multi-center Phase 3 clinical study of Probuphine in the treatment of opioid addiction.
SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- Data from a phase II study demonstrated that oral NKTR-118 improved lower gastrointestinal dysfunction by increasing the frequency of bowel movements in patients with opioid-induced constipation, while simultaneously preserving opioid-mediated analgesia.
Scientists at Georgia State University have uncovered the mechanisms of how pain in infancy alters how the brain processes pain in adulthood.
Discovery of way to balance effects of two drugs sets stage for safer pain relief.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.